Return to homepagePandemic Pact

Success Rate and Timeline for Development of Vaccines for Emerging and Reemerging Viral Infectious Diseases [Funder: MI4]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Kimmelman, Jonathan

  • Research Location

    Canada

  • Lead Research Institution

    McGill University

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

A vaccine is our end game for the COVID-19 pandemic. During the COVID-19 outbreak, various political leaders, public health officials and news commentators have discussed the prospect of a vaccine to stem the pandemic. Some commentators have hinted at the prospect of a vaccine being available within a year. While numerous advances in immunology, infrastructure, and molecular biology have greatly accelerated the process of identifying and testing new vaccine candidates, vaccine development-as with any pharmaceutical development-is unpredictable and time-consuming. Biomedical ethicist Dr. Jonathan Kimmelman, epidemiologist and vaccinologist Dr. Nicole Basta and pediatric infectious disease specialist Dr. Jesse Papenburg will use historic success rates for viral vaccine development to provide publicly accessible, evidence-based projections for when a COVID-19 vaccine might be available